Accumulating evidence indicates that Visinin-like protein-1 (VILIP-1), a member of the family of neuronal calcium sensor proteins (NCS), modulates a variety of processes in extra-neuronal tissues. In this study, we describe VILIP-1 expression in the human heart, rat cardiomyocytes, and H9c2 cells, and demonstrate that VILIP-1 regulates the cell surface localization of natriuretic peptide receptor B (NPR-B). In preparations from failing hearts, we observed VILIP-1 downregulation and reduced NPR-B signalling. In conclusion, VILIP-1 deficiency may be responsible for the reduced efficiency of the natriuretic peptide system in cardiac hypertrophy and heart failure and may therefore serve as pharmacological target.
Introduction
Neuronal calcium sensor proteins (NCS) comprise a family of more than 40 calcium-binding proteins belonging to the super-family of EF-hand proteins. This family includes members of recoverins, guanylyl cyclase-activating proteins (GCAPs), frequenins, K + -channel interacting proteins (KChIPs) and visinin-like proteins (VILIPs). VILIPs, including VILIP-1 to -3, hippocalcin, and neurocalcin-δ are differentially expressed throughout the nervous system [1] . Ca 2+ binding to the EF-hand motifs of NCS leads to conformational changes which facilitate binding to lipid bilayers via Ca 2+ -myristoyl switching [2] .
VILIPs have been shown to be implicated in a broad spectrum of physiological and pathophysiological processes including synaptic plasticity, hypertension, neuropathological diseases, cancer, and insulin secretion [3] [4] [5] [6] [7] [8] . These effects are possibly mediated by actions on membrane receptors and ion channels such as the natriuretic peptide receptor B (NPR-B) and the nicotinic acetylcholine receptor [9, 10] . VILIP-1 modulates clathrin-dependent receptor cycling in the central nervous system supporting its general role in membrane trafficking [9] . VILIP-1 has also been shown to regulate gene expression by formation of protein-RNA-complexes that modulate localization and stability of specific mRNAs and possibly by affecting the cAMP/CREB pathway [8, 11] .
VILIP-1 is expressed at high levels in the brain and its role in the central nervous system has been addressed in a number of studies [6, [11] [12] [13] . Expression of VILIP-1 was also reported for the heart, pancreas, reproductive organs, and colon, however, its function in extra-neuronal tissues is still poorly understood [14] .
The natriuretic peptides comprise a family of the structurally related but genetically distinct peptide hormones, atrial (ANP), brain (BNP) and C-type natriuretic peptide (CNP). They exert their biological actions by binding to cell surface receptors divided into particular guanylyl cyclase-coupled receptors NPR-A and -B and the clearance receptor NPR-C [15, 16] . NPR-B has recently been shown to mediate antihypertrophic actions of its ligand C-type natriuretic peptide in vitro and in vivo thereby serving as potential pharmacological target for the treatment of cardiac hypertrophy and heart failure [17] . Only a few factors that are involved in the regulation of NPR-B have been identified so far: The transcriptional factor Sp1, protein kinase C (PKC), Ca 2+ as well as VILIP-1 in neuronal cells [9, [18] [19] [20] .
This study was designed to analyze cardiac expression of VILIP-1 and its role in modulating NPR-B signalling in vitro and in failing hearts. 
Methods

Reagents and Materials
Immunocytochemistry
Cardiomyocytes were preparated as described [21, 22] . Methanol-fixed cells were washed with phosphate-buffered saline containing 0.1% Triton-X-100. Samples were blocked by using 2% normal donkey serum. Cells were incubated overnight at 4°C with a VILIP-1 antibody (1:1.000) [14] . On the next day, cells were incubated with an anti-rabbit Cy3-conjugated secondary antibody (1:500, Jackson
ImmunoResearch, West Grove PA) and mounted using Vectashield medium (Vector laboratories, Burlingame, CA). Fluorescent images were collected using a Leica DMI6000MB microscope.
Protein preparation, SDS-PAGE and Western blot
Samples were homogenized in RIPA buffer containing the "complete mini Protease inhibitor cocktail" (Roche, Mannheim, Germany). Proteins were isolated by centrifugation (5.000 x g, 10 min, 4°C), quantified by BCA method (Pierce, Rockford, USA), separated on a 12% Tris-Glycine gel (Serva, Heidelberg, Germany) and blotted onto a nitrocellulose membrane (Whatman, Dassel, Germany).
VILIP-1 was detected with the antibody described above and a horseradish peroxidase-conjugated anti-rabbit antibody (Sigma, Munich, Germany) using the ECL-Plus Western Detection System (GE Healthcare, Munich, Germany). The same membrane was stripped, GAPDH protein was detected with an mouse monoclonal antibody (GAPDH 6C5, Santa Cruz). 
Transfection of expression vectors and siRNA
Stimulation and determination of intracellular cGMP production
Cells were washed with PBS and stimulated with DMEM containing 1 mM IBMX, 0.5% BSA and CNP ranging from 1 nM to 1 µM for 20 minutes at 37°C. The reaction was stopped by placing culture dishes on ice and disrupting the cells by sonication. Determination of cGMP concentration was done by radioimmunoassay as described previously [23] . 
CNP-binding assay
Leucine incorporation
H9c2 cells overexpressing pEGFP-VILIP-1 (enhanced green fluorescent protein) or pEGFP were cultured in 12 well plates until 50% densitiy was reached. For inducing quiescence, DMEM containing 10% NCS was replaced by serum free medium. After incubation for 24 hours, cells were stimulated with 100 nM vasopressin alone or in combination with 50 nM CNP for 12 h at 37°C. L-(4,5)-3 HLeucine incorporation was performed as described. [17] . The L-(4,5)-3 H-Leucine incorporation of non-stimulated cells (basal) was set at 100%.
Experimental myocardial infarction
Experiments involving laboratory animals were conducted in accordance with the local authorities and conforming to the National Institutes of Health Guide for the Care and Use of Laboratory Animals (National Institutes of Health publication no. 85-23, revised 1996). Myocardial infarction was induced in Sprague Dawley rats (body weight 200 g) as described previously [24] . Four weeks after induction, cardiac function was assessed.
Echocardiography
Two-dimensional guided M-mode echocardiography was performed as described [17] .
Invasive hemodynamic measurement
Under anesthesisa with isoflurane, a 2-F catheter (Aria, Millar Instruments) was advanced into the right coronary artery and inserted into the left ventricle for measurement of contractility (dP/dt max ), relaxation (dP/dt min ) and left ventricular end-diastolic pressure (LVEDP). After hemodynamic measurement, rats were euthanized and the organs were rapidly dissected. The heart was dissected into the chambers and the scar was removed from the non-infarcted area. Samples were immediately frozen in liquid nitrogen and stored at -80°C until further analysis.
RNA-extraction, RNase Protection Assay and Real-time PCR
Total RNA was extracted with Trizol ® (Invitrogen; Karlsruhe, Germany) VILIP-1 and GAPDH transcripts were amplified by RT-PCR from pEGFP-VILIP-1 or from rat cDNA pool (Primer sequences: supplementary file). PCR fragments were cloned into pGEM-Teasy vector and antisense probes were labelled with [ 32 P]UTP (Promega). VILIP-1 and GAPDH expression was measured by RNase protection assay as described [17] .
For cDNA synthesis, 2 µg total RNA were reverse transcribed with oligo-dT (Omniscript, Qiagen).
Expression of NPR-B was analyzed by real-time PCR (TaqMan Master Mix, Applied Biosystems;
Primer sequences: supplementary file).
Preparation of membranes and guanylyl cyclase assay
The non-infarcted area of the left ventricle was homogenized in phosphatase inhibitor buffer containing 25 mM HEPES (pH 7.4), 50 mM NaCl, 20% glycerol, 50 mM NaF, 2mM EDTA, 0.5 µM microcystin and the protease inhibitor cocktail. After centrifugation at 10,000 x g for 10 min at 4 °C, the pellet was washed twice with the phosphatase inhibitor buffer. After resuspension, total protein concentration was determined by the Bradford method. Immediately after preparation 80 µg protein were used for assaying guanylyl cyclase activity as described [23] .
Determination of BNP plasma level
Plasma samples were purified on C18 Sep-Pak colums (Waters), BNP concentrations were determined by a radioimmunoassay (Bachem).
Statistical Analysis
The differences between groups were evaluated by analysis of variance (ANOVA), or paired Student`s t-test where appropriate. The significance level was set at p<0.05. All data are expressed as mean ± standard error of the mean (SEM).
Results
VILIP-1 is expressed in cardiomyocytes
VILIP-1 mRNA expression was tested in a broad range of tissues derived from Sprague Dawley rats by RNase protection assay. VILIP-1 was expressed in all organs tested including cardiac chambers.
The housekeeping gene GAPDH served as control (Fig. 1A) . VILIP-1 expression was detected by western blot in lysates from human and rat samples from the left ventricle as well as in H9c2 cells (single band of ~22 kDa; Fig. 1B ). The expression of VILIP-1 was confirmed by immunocytochemistry in cardiomyocytes and H9c2 cells (Fig. 1C-E) .
VILIP-1 regulates NPR-B membrane association in vitro
H9c2 cells are derived from rat embryonic cardiomyocytes and expresses VILIP-1 (Fig. 1B, E ) and NPR-B as confirmed by RT-PCR and enzyme activity studies [17, 23] . Cells were transfected with pEGFP-VILIP-1 or the empty vector (mock) and the expression was confirmed by the detection of the EGFP fluorescence ( Fig. 2A) .
Stimulation with CNP led to a dose-dependent increase of intracellular cGMP production in both groups. However, in VILIP-1 overexpressing H9c2 cells, CNP induced a significantly higher cGMP response ( Fig. 2A) . To determine the receptor density of NPR-B on the cell surface, cells were incubated with 125 I-CNP-22. These studies revealed an increased number of binding sites in VILIP-1 overexpressing H9c2 cells, confirming an increased number of NPR-B molecules at the cell surface (Fig. 2B) . In contrast, siRNA-induced reduction of VILIP-1 expression in H9c2 cells led to a decreased CNP-dependent cGMP response with a reduced binding of 125 I-CNP (Fig. 2C, D) .
VILIP-1 influences antihypertrophic potential of CNP in H9c2 cells
Arg-vasopressin induced a similar increase of protein synthesis in H9c2 cells stably transfected with VILIP-1 or mock. The hypertrophy was partially blocked by CNP in both groups. However, the potency of CNP to block the Arg-vasopressin effect was higher in VILIP-1-overexpressing cells (Fig.   3A) . In H9c2 cells with reduced VILIP-1 and controls, vasopressin exposure led to a similar protein synthesis. This process was prevented by CNP in H9c2 cells treated with unrelated siRNA, but not in those with reduced VILIP-1 expression (Fig. 3B) .
Induction of myocardial infarction in rats
Ligation of the LAD (left anterior descending artery) was performed to induce myocardial infarction (MI) of the left ventricle in rats. Echocardiography, invasive hemodynamic measurement and determination of plasma BNP was performed to determine cardiac dimensions, systolic and diastolic dysfunction ( Table 1) .
Cardiac hyporesponsiveness to CNP in experimental myocardial infarction
To determine cardiac responsiveness of NPR-B to hormonal stimulation, we prepared heart membranes from the non-infarcted area of the left ventricle or from a similar region of sham-operated animals and measured cGMP production upon stimulation with a saturating concentration of CNP (Fig. 4) . Basal guanylyl cyclase activity was comparable between both groups. The stimulation of membranes with Triton-X100/Mn 2+ are thought to reflect the changes of NPR activity resulting from changes in receptor protein or phorphorylation state of the regulatory domain. Guanylyl cyclase activity in the presence of Triton-X100/Mn 2+ was not significantly altered in cardiac membranes obtained from animals with MI. In contrast, the CNP-dependent cGMP-response in the hearts of rats with MI was significantly reduced to 66% (p<0.05) of the activity observed in hearts from shamoperated animals.
Expression of NPR-B, NPR-C and VILIP-1 in experimental myocardial infarction
To find an explanation for the reduced CNP-dependent cGMP-response, we first analyzed mRNA expression of NPR-B and VILIP-1 in the cardiac samples used for membrane preparations. Gene expression was normalized to GAPDH expression. The expression level of sham-operated animals was set at 100%. The expression of NPR-B was not altered in the infarct group (Sham: 100% ± 9 vs. MI 83% ± 6, p=0.14). The second part of this study was to explore a possible relevance of VILIP-1 in congestive heart failure. Increased cardiac expression of ANP and BNP and release of this peptides into the circulation is a characteristic feature in heart failure. Despite this elevation, the physiologic response to these peptides is diminished [33, 34] . Currently two studies were published describing hyporesponsiveness of cardiac and renal tissues to ANP in congestive heart failure. It could be demonstrated that for kidney membranes a reduced amount of NPR-A molecules and not a reduced phosphorylation state may explain the reduced enzymatic activity [35] .
For membrane preparations obtained from the non-infarcted area of rats four weeks after surgery, a reduced CNP-dependent cGMP response was detected. This finding is in accordance with the study from Kim et al., describing reduced NPR-B activity in membranes prepared from endocardial cells of the hypertrophied right ventricle [36] . Interestingly in failing hearts from mice with pressure-overload, guanylyl cyclase activity of NPR-B was not affected [37] . Thus the regulation of NPR´s seem to depend on several factors such as the origin of heart disease and tissue or differences among species.
A number of factors may be responsible for the reduced activity of NPR-B in the cardiac membranes obtained from rats with MI. These are increased expression of the clearance receptor NPR-C, activation of phosphatases that desensitize NPR-B, transcriptional regulation of NPR-B, alternative splicing of the primary transcript leading to dominant-negative NPR-B isoforms or increased receptor
internalization.
An increased expression of NPR-C was decribed in heart failure patients, rats with pressure overloadinduced cardiac hypertrophy and was also observed in our model [38, 39] . For guanylyl cyclase assays a saturating concentration of CNP was applied, so it is unlikely that a increased clearance is responsible for the reduced CNP-dependent cGMP response.
It is well described that PKC and Ca 2+ are able to reduce enzymatic activity of NPR-A and -B by activating at least two different phosphatases. This process is known as heterologous desensitization and is characterized by dephosphorylation of the regulatory domain of NPR-A and -B [40] [41] [42] . The study of Bryan et al. has demonstrated that receptor dephosphorylation is not the mechanism that lead to renal hyporesponsiveness to natriuretic peptides in heart failure [35] . There are no studies reported in which the phosphorylation state of NPR-A or -B have been determined in failing hearts. In the cardiac cell line H9c2, heterologous desensitization of NPR-A and -B can be induced within a few minutes by employing the PKC-activator PMA (phorbol 12-myristate 13-acetate). This effect is blocked by several PKC-inhibitors (unpublished data of J.B.). In heart failure PKC is activated by humoral factors, such as angiotensin, endothelin or catecholamines, so heterologous desensitization of NPR-B may be responsible for the reduced CNP-dependent cGMP response in our model [43] .
Furthermore, a reduced mRNA expression or membrane exposition may also be causative for the reduced guanylyl cyclase activity in our model. The gene expression of NPR-B in the noninfarcted part of the left ventricle was not altered. The same result was found in a model of pacing-induced heart failure in minipigs. In this model NPR-B expression was reduced in the right but not in the left ventricle [37] .
Given the possibility that VILIP-1 regulates the amount of NPR-B in cardiac membranes, as observed
in H9c2 cells, we tested mRNA expression and protein content in whole tissue homogenates. Whereas no significant reduction of mRNA expression was observed, a reduction of VILIP-1 protein level was detected. This may lead to a reduced exposition of NPR-B on the cell surface, explaining the reduced CNP-dependent cGMP-response. Due to the lack of suitable antibodies against NPR-B, including dominant-negative isoforms of this receptor, protein levels can not be determined so far [44] .
In summary, this study provides first evidence for a functional role of VILIP-1 in the heart. VILIP-1 may serve as important factor responsible for the downregulation of NPR´s in congestive heart failure.
It may therefore constitute a potential pharmacological target for the treatment of cardiac hypertrophy and heart failure. Table 1 : Heart failure parameters. Values are expressed as the means ± SEM. HW, heart weight; BW, body weight; LV, left ventricle; LVEDD, LV end-diastolic diameter; LVESD, LV end-systolic diameter; PWT, LV posterior wall thickness; LV FS, LV fractional shortening; LV EF, LV ejection fraction; dP/dtmax, LV contractility; dP/dtmin LV relaxation; LVEDP, LV end-diastolic pressure; BNP, brain natriuretic peptide. 
